U.S. markets closed

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
56.96+0.60 (+1.06%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close56.36
Bid53.00 x 800
Ask56.92 x 3000
Day's Range56.00 - 57.99
52 Week Range50.05 - 94.06
Avg. Volume355,952
Market Cap2.14B
Beta (5Y Monthly)2.53
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Earnings Season Could Be Great for Axsome Therapeutics (AXSM)

    Why Earnings Season Could Be Great for Axsome Therapeutics (AXSM)

    Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • 2 Top Biotech Stocks to Buy Right Now
    Motley Fool

    2 Top Biotech Stocks to Buy Right Now

    Novavax owners have watched their stock crush the market as the share price has run up 112% this year. Novavax, which is still working on a COVID-19 vaccine, rose 2,700% in 2020. Axsome, on the other hand, has no pharmaceuticals to prevent or treat COVID-19 -- it's focused on medicine for depression and migraines.

  • 3 Biotech Stocks That Could Be Millionaire-Makers
    Motley Fool

    3 Biotech Stocks That Could Be Millionaire-Makers

    Biotech companies are about the riskiest investment someone can find in the stock market. For every Amgen, which has gone from a market cap of less than $1 billion 30 years ago to $147 billion today, there are hundreds that fade into obscurity. Each stock has been beaten down but has the potential to inflate shareholders' portfolios if their science proves successful.